Oryzon Genomics S.A. is the first Spanish Biomarker and Target Discovery Company with an In-Vitro Diagnostics and Therapeutic R&D pipeline focused in oncology and neurodegenerative diseases.
Looking for a particular Crystax Pharmaceuticals / Oryzon Genomics employee's phone or email?
The Crystax Pharmaceuticals / Oryzon Genomics annual revenue was $9.1 million in 2026.
Tamara Maes is the Founder and Shareholder of Crystax Pharmaceuticals / Oryzon Genomics.
44 people are employed at Crystax Pharmaceuticals / Oryzon Genomics.
Crystax Pharmaceuticals / Oryzon Genomics is based in Cornella de Llobregat, Catalonia.
The NAICS codes for Crystax Pharmaceuticals / Oryzon Genomics are [541711, 54161, 541612, 54171, 5416, 54, 5417, 325, 32, 541].
The SIC codes for Crystax Pharmaceuticals / Oryzon Genomics are [283, 28].